300725 Pharma Block Sciences
- 35.26
- +0.37+1.06%
Pharma Block Sciences News
The China Securities Convertible Bonds Index fell 0.08% at the beginning of the session, Xuerong Convertible fell by more than 4%, Kirin Convertible Bonds fell by more than 2%; Yakshi Convertible and Baichuan Convertible Bonds rose more than 5%.
The China Securities Convertible Bonds Index fell 0.08% at the beginning of the session, Xuerong Convertible fell by more than 4%, Kirin Convertible Bonds fell by more than 2%; Yakshi Convertible and Baichuan Convertible Bonds rose more than 5%.
Yakishi Technology: The board of directors proposed to revise the “Yakushi to Bond” conversion price downward
Yakshi Technology announced that from April 17, 2024 to May 10, 2024, the closing price of the company's stock for 15 trading days was lower than 85% of the current conversion price of “Yakishi Bonds” (i.e. 69.22 yuan/share), which has triggered the downward revision of the share conversion price specified in the company's prospectus. The board of directors of the company proposed a downward revision of the “Yakushi to Bonds” conversion price and submitted the bill to the Company's Extraordinary General Meeting of Shareholders for consideration.
Pharmaceutical Stone Technology (300725) Annual Report Review Report: CDMO sector grows steadily, profit side is under pressure in the short term
The company released its 2023 annual report and 2024 quarterly report. For the full year of 2023, the company achieved operating income of 1.73 billion yuan, an increase of 8.2% over the previous year; achieved net profit of 200 million yuan, a year-on-year decrease of 37.2%; deducted not to the mother
Pharmaceutical Stone Technology (300725.SZ): Revenue from foreign customers accounted for 68.48% in 2023
Gelonghui, May 9丨Pharmaceutical Stone Technology (300725.SZ) said on the investor interactive platform that our products and services are mainly used in pharmaceutical companies' new drug research and development projects. Judging from the global innovative drug development pattern, overseas companies dominate, so the company's revenue mainly comes from overseas. In 2023, revenue from foreign customers accounted for 68.48%.
Pharmaceutical Stone Technology (300725): CDMO's steady development continues to consolidate its technical advantages
The 2023 and 2024Q1 results were lower than our expectations for 2023, with revenue of $1,725 million, +8.18% YoY, and net profit to mother of $197 million, or -37.19% YoY. Net profit after deducting non-return to mother is 1
Pharmaceutical Stone Technology (300725): Profit side is under phased pressure to continue to expand the field of new chemical physical pharmaceuticals
Multiple factors put pressure on the profit side. In 2023, the number of customers served continued to increase. The company achieved revenue of 1,725 billion yuan, an increase of 8.18% over the previous year; net profit to mother was 197 million yuan, a year-on-year decrease of 37.19%;
Pharmaceutical Stone Technology (300725): Demand contraction affects growth rate in many ways to respond to industry changes
Matters: (1) The company released its 2023 annual report, achieving full-year revenue of 1,725 billion yuan (+8.18%), net profit to mother of 197 million yuan (-37.19%), and net profit of 176 million yuan after deducting non-return to mother (-3)
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of s
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of service customers continues to increase; 2) the design of a series of molecular blocks required for the development of new chemical physical drugs based on market demand; 3) the CDMO pipeline continues to expand, production capacity construction progresses steadily, and continues to empower global customers. (Mainichi Keizai Shimbun)
Yakishi Technology (300725): Steady revenue growth and profitability is expected to improve
Maintain an increase in holdings rating. 2023 revenue of 1,725 million yuan (+8.18%), net profit to mother of 197 million yuan (-37.19%); 2024Q1 revenue of 377 million yuan (-1.56%),
Yakishi Technology (300725): Customer pipeline continues to expand, CDMO business continues to grow
In '23, the company achieved operating income of 1,725 billion yuan (+8.18%); net profit to mother of 197 million yuan (-37.19%); deducted non-176 million yuan (-33.81%); sales/management/R&D expenses
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
Yakishi Technology (300725): Front-end business gradually recovers, waiting for the industry to gradually reach an inflection point
Incident: The company released its 2023 annual report and 2024 quarterly report, 1) In 2023, the company achieved operating income of 1,725 billion yuan, an increase of 8.18% over the previous year; net profit to mother was 197 million yuan, a year-on-year decrease of 3
Yakishi Technology: No downward revision of the “Yakushi to Bond” conversion price
Nanjing Yakushi Technology Co., Ltd. announced that the company has triggered a downward revision of the “Yakushi to Bond” share conversion price. On April 16, 2024, after review and approval at the 29th meeting of the 3rd board of directors, the board of directors decided not to revise the share conversion price downward for the time being.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
Pharmaceutical Stone Technology (300725.SZ): A one-stop innovative CRDMO service provider in the field of global pharmaceutical R&D and manufacturing
Gelonghui March 29丨Pharmaceutical Stone Technology (300725.SZ) said on the investor interactive platform that our company is a one-stop innovative CRDMO service provider in the field of global pharmaceutical R&D and manufacturing. The company helps drug discovery with its novel and unique molecular blocks and related compound library screening technology; and has built an integrated CRDMO service platform to provide process development and production services for efficient and high-quality intermediates, APIs and pharmaceutical preparations for innovative drug development and commercialization projects. The specific products and services provided by the company mainly depend on the partner's project requirements.
Yakshi Technology won the 2024 ACS CMO Green Chemistry Excellence Award
Nanjing, March 26, 2024 /PRNewswire/ -- Nanjing Pharmaceutical Technology Co., Ltd. (Company abbreviation: “Pharmaceutical Stone Technology”, stock code: 300725.SZSE), as a global integrated CRDMO company focusing on innovative chemistry and low-carbon manufacturing, recently won the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (Green Chemistry Institute Pharmaceutical) Roundtable,
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMO with a focus on innovative chemistry and low-carbon manufacturing, is proud to an
Express News | Yakishi Technology: The application of AI technology in the company's new drug discovery service is currently in the early stages of development
[BT Financial Report Momentary Analysis] Yakshi Technology's 2023 Quarterly Report: Financial Perspectives Behind Steady Growth in Performance
Pharmaceutical Stone Technology (stock code: 300725), as a global leader in pharmaceutical R&D and manufacturing, provides one-stop services from molecular block development to drug discovery solutions. The company focuses on chemical and low-carbon technology innovation, and is committed to improving the efficiency of new drug discovery and development while reducing drug production costs. Yakshi Technology's molecular block library is rich in variety, novel in structure and efficient, and has successfully covered many key stages of new drug development. In terms of assets and liabilities, Yakshi Technology's 2023 three-quarter report shows that the company's total assets reached 5.217 billion yuan, up from 4.862 billion yuan at the end of the previous year
Pharmaceutical Stone Technology (300725.SZ): As of December 29, 2023, the number of shareholders of the company was 30,363
Gelonghui, January 5, 丨 Yakshi Technology (300725.SZ) said on the investor interactive platform that as of December 29, 2023, the number of shareholders of the company was 30,363.
Analysis
Price Target
No Data
